In the first of a series of vlogs, Professor Wilkie describes what personalised medicine means to him and his research.

In our series of vlogs, Professor Hallowell describes what personalised medicine means to her and her research.

In our series of vlogs, Dr Douglas describes what personalised medicine means to him and his research.

In our series of vlogs, Dr Martin-Geary describes what personalised medicine means to her and her research.

In our series of vlogs, Dr Short describes what personalised medicine means to him and his research. Dr Short is co-founder and CEO of Sano Genetics.

In our series of vlogs, Dr Ellingford describes what personalised medicine means to him and his research. Dr Ellingford is a Research Fellow at the University of Manchester, where his group applies genomics, transcriptomics, bioinformatics, computational biology and functional biology to understand normal cell/tissue function and to the study of genetic diseases, including rare genomic disorders and cancer.

In our series of vlogs, Dr Foreman describes what personalised medicine means to her and her research. Dr Foreman is a DECIPHER Project Manager at the Sanger Institute.

In our series of vlogs, Dr Blair describes what personalised medicine means to him and his research. Dr Edward Blair is a consultant Clinical Geneticist with specialist interests in Inherited Cardiac Conditions and Marfan syndrome.

In our series of vlogs, Professor Newman describes what personalised medicine means to him and his research. Dr Newman is a Clinical Senior Lecturer at the University of Manchester, and Honorary Consultant in Genetic Medicine since 2004.

In our series of vlogs, Dr Stanton describes what personalised medicine means to her and her research. Emma joined Oxford Nanopore in 2020 as Clinical VP. She is also its first Head of Oxford Nanopore Diagnostics (OND). In this role, she supports its ambitions for growth in healthcare applications. Emma is excited about the opportunity to grow a diagnostics business that applies technology to health care in a targeted way. Over time, this will make a huge difference to patients and their families. Until November 2020, Emma was Director for Supplies and Innovation as part of the British government’s NHS Test and Trace response to COVID-19. Prior to this, Emma was CEO of Four Eyes Insight, Chief Partnership Officer for Beacon Health Options (Northeast USA) and CEO of Beacon in the UK. Emma has also been a Commonwealth Fund Harkness Fellow in Healthcare Policy and Practice and a Senior Associate at the Institute for Strategy and Competitiveness, both at Harvard University. Prior to this, Emma was a practicing clinician in the National Health Service (NHS). Emma holds an Executive MBA from Imperial College London, a MRCPsych from the Royal College of Psychiatrists and a Bachelor of Medicine from Southampton University.